INmune Bio Secures MHRA PIP Approval for Ebstrocel in RDEB
Event summary
- INmune Bio received MHRA approval for its Pediatric Investigation Plan (PIP) for Ebstrocel™, accelerating regulatory path in the UK.
- The PIP approval was achieved in under three months, ahead of the expected ten-month review cycle.
- Ebstrocel™ targets Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare and severe pediatric disease affecting ~300 children in the UK.
- MHRA alignment on key elements reduces regulatory uncertainty for the planned 2026 Marketing Authorization Application (MAA).
- INmune Bio is now preparing final commercial manufacturing steps for Ebstrocel™ authorization.
The big picture
INmune Bio’s PIP approval de-risks its regulatory path for Ebstrocel™, a first-in-class treatment for RDEB. The MHRA’s endorsement validates the clinical data package and supports INmune Bio’s twin-track strategy of conditional approval followed by confirmatory trials. This milestone positions the company to address a critical unmet need in rare pediatric diseases while advancing its broader CORDStrom™ platform.
What we're watching
- Regulatory Momentum
- Whether the MHRA’s accelerated review sets a precedent for faster approvals in other jurisdictions.
- Commercialization Timing
- The pace at which INmune Bio can finalize commercial manufacturing and file its MAA by year-end 2026.
- Market Access Strategy
- How early market access via conditional approval will impact Ebstrocel’s adoption in the UK and EU.
Related topics